---
title: "Earnings Scheduled For March 27, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280784337.md"
description: "Before the market opens on March 27, 2026, several companies will report their earnings. Instil Bio (NASDAQ: TIL) will release its fourth-quarter earnings. BioXcel Therapeutics (NASDAQ: BTAI) is expected to announce a quarterly loss of $0.52 per share with revenue of $142 thousand. Legence (NASDAQ: LGN) is projected to report earnings of $0.02 per share and $618.01 million in revenue. Werewolf Therapeutics (NASDAQ: HOWL) anticipates a quarterly loss of $0.34 per share with $600 thousand in revenue. Humacyte (NASDAQ: HUMA) is estimated to post a loss of $0.13 per share on $1.44 million revenue. Autolus Therapeutics (NASDAQ: AUTL) is projected to report a loss of $0.38 per share."
datetime: "2026-03-27T11:11:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280784337.md)
  - [en](https://longbridge.com/en/news/280784337.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280784337.md)
---

# Earnings Scheduled For March 27, 2026

### Companies Reporting Before The Bell

• Instil Bio (NASDAQ:TIL) is expected to report earnings for its fourth quarter.

• BioXcel Therapeutics (NASDAQ:BTAI) is projected to report quarterly loss at $0.52 per share on revenue of $142 thousand.

• Legence (NASDAQ:LGN) is expected to report quarterly earnings at $0.02 per share on revenue of $618.01 million.

• Werewolf Therapeutics (NASDAQ:HOWL) is likely to report quarterly loss at $0.34 per share on revenue of $600 thousand.

• Humacyte (NASDAQ:HUMA) is estimated to report quarterly loss at $0.13 per share on revenue of $1.44 million.

• Autolus Therapeutics (NASDAQ:AUTL) is projected to report quarterly loss at $0.38 per share on revenue of $23.24 million.

• SBC Medical Group Holding (NASDAQ:SBC) is likely to report quarterly earnings at $0.12 per share on revenue of $46.06 million.

• Yunji (NASDAQ:YJ) is likely to report earnings for its Fiscal Year 2025.

• Huize Holding (NASDAQ:HUIZ) is estimated to report earnings for its Fiscal Year 2025.

• 51 Talk Online Education (AMEX:COE) is likely to report earnings for its fourth quarter.

• Kopin (NASDAQ:KOPN) is projected to report quarterly loss at $0.01 per share on revenue of $11.65 million.

• LM Funding America (NASDAQ:LMFA) is expected to report quarterly loss at $0.45 per share on revenue of $2.80 million.

• TMC The Metals Co (NASDAQ:TMC) is projected to report earnings for its fourth quarter.

• Super League Enterprise (NASDAQ:SLE) is projected to report quarterly loss at $2.98 per share on revenue of $3.58 million.

### Companies Reporting After The Bell

• Origin Materials (NASDAQ:ORGN) is likely to report earnings for its fourth quarter.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [LGN.US](https://longbridge.com/en/quote/LGN.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [AUTL.US](https://longbridge.com/en/quote/AUTL.US.md)
- [BTAI.US](https://longbridge.com/en/quote/BTAI.US.md)
- [HOWL.US](https://longbridge.com/en/quote/HOWL.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [TIL.US](https://longbridge.com/en/quote/TIL.US.md)
- [HUMA.US](https://longbridge.com/en/quote/HUMA.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)

## Related News & Research

- [Luke Evnin Sells 22,184 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock](https://longbridge.com/en/news/287219594.md)
- [Goldman Sachs Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)](https://longbridge.com/en/news/286522682.md)
- [Instil Bio Q1 net loss narrows on lower R&D expenses](https://longbridge.com/en/news/286553757.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)